MIT spinout Elicio developed a vaccine based on a lymph node-targeting approach first developed at the Koch Institute. Phase 1 solid tumor clinical trial results are promising so far.
Two professors and three additional alumni recognized for “dreaming up solutions to global challenges — advancing health, sustainability, and human connection.”
Awarded $65.67 million from ARPA-H, the researchers will work to develop ingestible capsules that deliver mRNA and electric stimuli to treat metabolic disorders such as diabetes.
Team-based targeted projects, multi-mentor fellowships ensure that scientists studying social cognition, behavior, and autism integrate multiple perspectives and approaches to pressing questions.